{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:05:04Z","timestamp":1790971504552,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.metabol.2024.155958","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T16:43:06Z","timestamp":1719420186000},"page":"155958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019"],"prefix":"10.1016","volume":"158","author":[{"given":"Pojsakorn","family":"Danpanichkul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokphong","family":"Suparan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyata","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuthathip","family":"Kaeosri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banthoon","family":"Sukphutanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narathorn","family":"Kulthamrongsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Methasit","family":"Jaisa-aad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Han","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Antonio","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karn","family":"Wijarnpreecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.155958_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.01.026","article-title":"Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties","volume":"79","author":"Allen","year":"2023","journal-title":"J Hepatol"},{"issue":"414\u2013428","key":"10.1016\/j.metabol.2024.155958_bb0010","article-title":"The global burden of metabolic disease: data from 2000 to 2019","volume":"35","author":"Chew","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2024.155958_bb0015","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/apt.17714","article-title":"The silent burden of non-alcoholic fatty liver disease in the elderly: a global burden of disease analysis","volume":"58","author":"Danpanichkul","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.155958_bb0020","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.155958_bb0025","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/HEP.0000000000000361","article-title":"The global fatty liver disease sustainable development goal country score for 195 countries and territories","volume":"78","author":"Lazarus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.155958_bb0030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.155958_bb0035","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.155958_bb0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FJC.0000000000001418","article-title":"Nonalcoholic fatty liver disease as an emerging risk factor and potential intervention target for atherosclerotic cardiovascular diseases","volume":"81","author":"Zhang","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.metabol.2024.155958_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.676044","article-title":"The transition from undernutrition to overnutrition under adverse environments and poverty: the risk for chronic diseases","volume":"8","author":"Leocadio","year":"2021","journal-title":"Front Nutr"},{"key":"10.1016\/j.metabol.2024.155958_bb0050","doi-asserted-by":"crossref","first-page":"e899","DOI":"10.1016\/S2214-109X(21)00143-1","article-title":"Global health in low-income and middle-income countries: a framework for action","volume":"9","author":"Olufadewa","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.metabol.2024.155958_bb0055","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/europace\/euac237","article-title":"Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2019","volume":"25","author":"Dong","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.metabol.2024.155958_bb0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021","volume":"402","author":"Collaborators","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.155958_bb0065","doi-asserted-by":"crossref","first-page":"e1553","DOI":"10.1016\/S2214-109X(23)00355-8","article-title":"Global burden of peripheral artery disease and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"11","author":"Collaborators","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.metabol.2024.155958_bb0070","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Diseases","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.155958_bb0075","article-title":"Metabolic syndrome and metabolic dysfunction-associated Steatotic liver disease in premenopausal women: global trends and projections to 2040","volume":"24","author":"Danpanichkul","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.metabol.2024.155958_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0085","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0090","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.jhep.2023.12.030","article-title":"Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia","volume":"80","author":"Nakano","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0095","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.jhep.2024.02.010","article-title":"Changing from NAFLD to MASLD: the implications for health-related quality of life data","volume":"80","author":"Hashida","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3350\/cmh.2023.0437","article-title":"Changing from NAFLD to MASLD: similar cumulative incidence of reflux esophagitis between NAFLD and MASLD","volume":"30","author":"Fukunaga","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3350\/cmh.2023.0557","article-title":"Changing from NAFLD to MASLD: similar prognosis of patients with HCC under atezolizumab\/bevacizumab treatment between NAFLD and MASLD","volume":"30","author":"Suzuki","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0110","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030438","article-title":"Global burden of atrial fibrillation and flutter by national income: results from the global burden of disease 2019 database","volume":"12","author":"Ohlrogge","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2024.155958_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253073","article-title":"Burden of disease among the world\u2019s poorest billion people: an expert-informed secondary analysis of Global Burden of Disease estimates","volume":"16","author":"Coates","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.155958_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12882-021-02597-3","article-title":"Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990-2019: results from the global burden of disease study 2019","volume":"23","author":"Ke","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.metabol.2024.155958_bb0125","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.155958_bb0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13690-023-01183-3","article-title":"The quality of care index for low back pain: a systematic analysis of the global burden of disease study 1990-2017","volume":"81","author":"Ghafouri","year":"2023","journal-title":"Arch Public Health"},{"key":"10.1016\/j.metabol.2024.155958_bb0135","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1210\/jc.2008-1595","article-title":"Obesity and the metabolic syndrome in developing countries","volume":"93","author":"Misra","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.155958_bb0140","doi-asserted-by":"crossref","first-page":"e895","DOI":"10.1016\/S2214-109X(16)30217-0","article-title":"The commercial determinants of health","volume":"4","author":"Kickbusch","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.metabol.2024.155958_bb0145","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-074336","article-title":"Implementing a package of essential non-communicable diseases interventions in low- and middle-income countries: a realist review protocol","volume":"13","author":"Vaidya","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.metabol.2024.155958_bb0160","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S2468-1253(22)00008-5","article-title":"The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas","volume":"7","author":"D\u00edaz","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0165","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","article-title":"A global research priority agenda to advance public health responses to fatty liver disease","volume":"79","author":"Lazarus","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0170","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2023.11.006","article-title":"Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes","volume":"80","author":"D\u00edaz","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0175","first-page":"13","article-title":"What is new in metabolic dysfunction-associated steatotic liver disease in lean individuals: from bench to bedside","author":"Danpanichkul","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2024.155958_bb0180","first-page":"12","article-title":"Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective","author":"Eskridge","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2024.155958_bb0185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bjsports-2020-103640","article-title":"Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries","volume":"56","author":"Katzmarzyk","year":"2022","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.metabol.2024.155958_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155402","article-title":"The global syndemic of metabolic diseases in the young adult population: a consortium of trends and projections from the Global Burden of Disease 2000-2019","volume":"141","author":"Chong","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155958_bb0195","doi-asserted-by":"crossref","first-page":"4134937","DOI":"10.1155\/2019\/4134937","article-title":"The burden of undiagnosed diabetes mellitus in adult African population: a systematic review and meta-analysis","volume":"2019","author":"Asmelash","year":"2019","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.metabol.2024.155958_bb0200","article-title":"Rising global burden of cancer attributable to high BMI from 2010 to 2019","volume":"152","author":"Tan","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155958_bb0205","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.155958_bb0210","first-page":"8","article-title":"Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM","author":"Hayward","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.metabol.2024.155958_bb0215","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.31726","article-title":"Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement","volume":"74","author":"Hagstrom","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.155958_bb0220","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","article-title":"Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week","volume":"79","author":"Mantovani","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.155958_bb0225","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.dld.2018.09.004","article-title":"Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"50","author":"Wijarnpreecha","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.metabol.2024.155958_bb0230","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/liv.15880","article-title":"Disparities among ethnic groups in mortality and outcomes among adults with MASLD: a multicenter study","volume":"44","author":"Aboona","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2024.155958_bb0235","doi-asserted-by":"crossref","unstructured":"Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun 2023;7.","DOI":"10.1097\/HC9.0000000000000251"},{"key":"10.1016\/j.metabol.2024.155958_bb0240","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.cmet.2023.06.012","article-title":"Nonalcoholic fatty liver disease mortality may not be decreasing: a need for careful interpretation of GBD 2019 estimates of liver deaths","volume":"35","author":"Paik","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2024.155958_bb0245","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"1330\u20131332","key":"10.1016\/j.metabol.2024.155958_bb0250","article-title":"Prevalence of Steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020","volume":"22","author":"Kalligeros","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.155958_bb0255","article-title":"Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly","volume":"6","author":"Danpanichkul","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.metabol.2024.155958_bb0260","doi-asserted-by":"crossref","DOI":"10.1111\/apt.18095","article-title":"Socio-economic association of alcohol use disorder and cardiovascular and alcohol-associated liver disease from 2010 to 2019","author":"Danpanichkul","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.155958_bb0265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s41669-022-00370-2","article-title":"Early cost-effectiveness and price threshold analyses of resmetirom: an investigational treatment for management of nonalcoholic steatohepatitis","volume":"7","author":"Javanbakht","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.metabol.2024.155958_bb0270","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2024.155958_bb0275","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.155958_bb0280","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc Med"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524001859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524001859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T20:14:29Z","timestamp":1732306469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524001859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":56,"alternative-id":["S0026049524001859"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155958","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155958"}}